secwatch.observer — SEC 8-K summary
======================================

Issuer:     Outlook Therapeutics, Inc. (OTLK)
CIK:        0001649989
Form:       8-K
Filed at:   2025-09-05T23:59:59+00:00
Accession:  0001104659-25-087886
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Chief Commercial Officer Jeff Evanson departs Outlook Therapeutics effective immediately
--------------------------------------------------------------------------------

- Jeff Evanson stepped down as Chief Commercial Officer on September 5, 2025.
- Departure is without 'cause'; eligible for severance benefits per employment agreement.
- No replacement named; interim CEO Lawrence Kenyon continues in role.
- Company is a biopharmaceutical firm focused on ophthalmic therapies.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1649989/000110465925087886/0001104659-25-087886-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1649989/000110465925087886/tm2525276d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-087886

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer